$AMGN News
Last published 12h ago
- 12h agoAMGNAMGEN ANNOUNCES POSITIVE PHASE 3 RESULTS FOR DAZODALIBEP IN SJÖGREN'S DISEASEPR NewswireAmgen (NASDAQ: AMGN) today announced results from the Phase 3 OASIZ-301 study of dazodalibep, the only global Phase 3 trial to demonstrate...
- 2d agoAMGNNEW DATA AT AHA 2026 DEMONSTRATES THE VALUE OF TREATMENT WITH REPATHA® EARLIER IN THE CARDIOVASCULAR RISK CONTINUUMPR NewswireAmgen (NASDAQ: AMGN) today announced new data at the American Heart Association (AHA) Scientific Sessions 2026 that further strengthen the case...
- 2d agoAMGNLLYHIMSIndices Hunt for Support After Steep Weekly Losses as Volatility Gauge Stays ElevatedPR NewswireStock Preachers News Commentary - Wall Street opens a new week nursing bruises from a rough stretch that sent every major index lower, with the...
- 1w agoAMGNAMGEN INC - EARNINGS RELEASEEarnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w ago.IXIC.SPX.DJIAAPL+9Cramer’s week ahead: Expect more volatility as tech earnings, midterms loomCNBCInvestors await earnings from Apple, AMD, and other major companies, as well as the midterm elections and the monthly jobs report.
- 2w agoAMGNAMGEN ANNOUNCES WEBCAST OF 2026 THIRD QUARTER FINANCIAL RESULTSPR NewswireTHOUSAND OAKS, Calif., Oct. 28, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its third quarter 2026 financial results on Tuesday, November 3, 2026, after the close of the U.S. financial
- 2w agoAMGNAMGEN TO PRESENT NEW DATA ACROSS RARE AND OTHER SERIOUS AUTOIMMUNE DISEASES AT ACR CONVERGENCE 2026PR NewswirePhase 3 OASIZ-301 Study of Dazodalibep in Sjögren's Disease Shows Statistically Significant and Clinically Meaningful Improvement in Systemic Disease Activity and Patient-Reported DrynessNew Long-Term UPLIZNA Data
- 2w agoAMGNAMGEN APPOINTS DAVID W. GIBBS TO BOARD OF DIRECTORSPR NewswireTHOUSAND OAKS, Calif., Oct. 26, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the appointment of David W. Gibbs to its Board of Directors, effective immediately. Gibbs will serve on the Board's Audit
- 2w agoAMGNAZNAmgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancerCNBCA drug from Amgen could give patients with an aggressive form of lung cancer significantly more time to live when added to an immunotherapy from AstraZeneca.
- 2w agoAMGNIMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCERPR NewswireNearly 80% of Patients Were Alive at One Year Versus 53% with IMFINZI Alone and Progression-Free Survival More Than TripledLate-Breaking Phase 3 DeLLphi-305 Results Presented in ESMO Presidential Symposium and
- 2w agoAMGNApproval of Pavblu, Bla #761298FDA Approved DrugsApproval Date: 10/23/2026; Drug Name: Pavblu, Bla #761298; Active Ingredients: AFLIBERCEPT-AYYH; Company: Amgen Inc; Submission Status: Approval; Application Number: 761298
- 3w agoAMGNAMGEN TO PRESENT AT THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS 2026PR NewswireTHOUSAND OAKS, Calif., Oct. 20, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the European Society of Medical Oncology Congress (ESMO) 2026 on
- 3w agoAMGNTEZSPIRE® DELIVERED HISTOLOGIC REMISSION AND SYMPTOM IMPROVEMENT IN EOSINOPHILIC ESOPHAGITISPR NewswireSymptom Improvements Versus Placebo at Week 24 Were Sustained Through Week 52 Statistically Significant Total Endoscopic Remission with No Visible Inflammation or Fibrosis Attained Versus Placebo at Week 52THOUSAND
- 1mo agoAMGNApproval of Repatha, Bla #125522FDA Approved DrugsApproval Date: 10/09/2026; Drug Name: Repatha, Bla #125522; Active Ingredients: EVOLOCUMAB; Company: Amgen Inc; Submission Status: Approval; Application Number: 125522
- 1mo agoAMGNApproval of Riabni, Bla #761140FDA Approved DrugsApproval Date: 09/29/2026; Drug Name: Riabni, Bla #761140; Active Ingredients: RITUXIMAB-ARRX; Company: Amgen Inc; Submission Status: Approval; Application Number: 761140
- 1mo agoONCYRVMDAMGNLLY+1KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034PR NewswireEquity Insider News Commentary - For most of the last four decades, RAS was the target oncology could not hit. That has changed quickly, and the...
- 1mo agoAMGNAMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASEPR NewswireAmgen (NASDAQ:AMGN) today announced positive topline results from the Phase 3 OASIZ 301 study evaluating dazodalibep in adults with Sjögren's disease ...
- 1mo agoAMGNMorgan Stanley 24th Annual Global Healthcare Conference - AMGEN INCEarnings Call TranscriptsAll right. Thanks for joining us, everybody. I'm Terrence Flynn, Morgan Stanley's U.S. Biopharma Analyst. For important disclosures, please see Morgan Stanleyís Research Disclosure website at www.morganstanley.com backsl
- 1mo agoAMGNFDA APPROVES REDUCED MONITORING TIME FOR FIRST TWO DOSES OF IMDELLTRA®PR NewswireAmgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) approved an update to the IMDELLTRA® (tarlatamab-dlle)...
- 2mo agoAMGNApproval of Imdelltra, Bla #761344FDA Approved DrugsApproval Date: 09/11/2026; Drug Name: Imdelltra, Bla #761344; Active Ingredients: TARLATAMAB-DLLE; Company: Amgen Inc; Submission Status: Approval; Application Number: 761344
- 2mo agoAMGNWELLS FARGO 21ST ANNUAL HEALTHCARE CONFERENCE - AMGEN INCEarnings Call TranscriptsAwesome. Thank you very much for joining us again today. My name is Mohit Bansal. I'm one of the biotech and pharma analysts here at Wells Fargo. And I have a pleasure to introduce the Amgen management team with us today
- 2mo agoAMGNAMGEN INC WELLS FARGO 21ST ANNUAL HEALTHCARE CONFERENCE - AMGEN INCEarnings Call TranscriptsAwesome. Thank you very much for joining us again today. My name is Mohit Bansal. I'm one of the biotech and pharma analysts here at Wells Fargo. And I have a pleasure to introduce the Amgen management team with us today
- 2mo agoAMGNAMGEN TO PRESENT AT THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCEPR NewswireAmgen (NASDAQ:AMGN) will present at the Morgan Stanley 24th Annual Global Healthcare Conference at 11:30 a.m. ET on Tuesday, September 15, 2026. Jay...
- 2mo agoGEBAHOODAFRM+10Jim Cramer says investors are too focused on AI stocks. Here’s where he says to look insteadCNBCCNBC's Jim Cramer said investors should look beyond the AI data-center trade as compelling opportunities emerge in other areas of the market.
- 2mo agoAMGNIMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCERPR NewswireAmgen (NASDAQ: AMGN) today announced landmark results from the Phase 3 DeLLphi-305 study, which met its primary endpoint at a pre-specified interim...
- 2mo agoNVSIONSAMGNLLY+1Cholesterol drug setback casts doubt over multibillion-dollar raceCNBCNovartis’ failure raises the stakes for Amgen and Eli Lilly in the race to turn lower Lp(a) levels into fewer heart attacks and strokes.
- 2mo agoAMGNAMGEN TO PRESENT AT THE 2026 WELLS FARGO HEALTHCARE CONFERENCEPR NewswireAmgen (NASDAQ: AMGN) will present at the 2026 Wells Fargo Healthcare Conference at 11:00 a.m. ET on Thursday, September 10, 2026. Thomas Dittrich,...
- 2mo agoAMGNAMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKEPR NewswireAmgen (NASDAQ: AMGN) today announced new findings showing Repatha® (evolocumab) reduced the risk of death in high-risk adults without a prior heart...
- 2mo agoAMGNTEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTSPR NewswireAmgen (NASDAQ:AMGN) and AstraZeneca today announced positive top-line results from the Phase 3 CROSSING trial of TEZSPIRE® (tezepelumab-ekko) in...
- 3mo agoAMGNAMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTSPR NewswireAmgen (NASDAQ: AMGN) today announced financial results for the second quarter of 2026. "Our results demonstrate strong performance across our...
- 3mo agoAMGNApproval of Neulasta, Bla #125031FDA Approved DrugsApproval Date: 08/04/2026; Drug Name: Neulasta, Bla #125031; Active Ingredients: PEGFILGRASTIM; Company: Amgen; Submission Status: Approval; Application Number: 125031
- 3mo agoAMGNAMGEN ANNOUNCES 2026 THIRD QUARTER DIVIDENDPR NewswireAmgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.52 per share dividend for the third quarter of 2026. The dividend will...
- 3mo agoAMGNPOSITIVE CHMP OPINION SUPPORTS BROADER USE OF AMGEN'S REPATHA® BEFORE A FIRST HEART ATTACK OR STROKEPR NewswireAmgen (NASDAQ: AMGN) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a...
- 3mo agoAMGNAMGEN ANNOUNCES WEBCAST OF 2026 SECOND QUARTER FINANCIAL RESULTSPR NewswireAmgen (NASDAQ:AMGN) today announced that it will report its second quarter 2026 financial results on Tuesday, August 4, 2026, after the close of the...
- 3mo agoAMGNApproval of Neupogen, Bla #103353FDA Approved DrugsApproval Date: 07/16/2026; Drug Name: Neupogen, Bla #103353; Active Ingredients: FILGRASTIM; Company: Amgen; Submission Status: Approval; Application Number: 103353
- 4mo agoLLYRVMDAMGNPFEReed Jobs would rather talk about curing cancer than his last nameTechCrunch
- 4mo agoAMGNMRNATMONVOAnthropic’s Claude Science bets on workflow, not a new model, to win over scientistsTechCrunch
- 4mo agoAMGNApproval of Xgeva, Bla #125320FDA Approved DrugsApproval Date: 06/23/2026; Drug Name: Xgeva, Bla #125320; Active Ingredients: DENOSUMAB; Company: Amgen; Submission Status: Approval; Application Number: 125320
- 4mo agoAMGNApproval of Prolia, Bla #125320FDA Approved DrugsApproval Date: 06/23/2026; Drug Name: Prolia, Bla #125320; Active Ingredients: DENOSUMAB; Company: Amgen; Submission Status: Approval; Application Number: 125320
- 5mo agoAZNNVOZLDPFROP-CH+3Drugmakers race to find a place in the next wave of obesity drugsCNBCDrugmakers are betting they can crack into the obesity drug market that Novo Nordisk and Eli Lilly currently dominate.
- 5mo agoAMGNAMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONSPR NewswireAmgen (NASDAQ:AMGN) today announced new data at the American Diabetes Association (ADA) 86th Scientific Sessions reinforcing its commitment to...
- 5mo agoAMGNAMGEN TO PRESENT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCEPR NewswireAmgen (NASDAQ:AMGN) will present at the Goldman Sachs 47th Annual Global Healthcare Conference at 9:20 a.m. ET on Tuesday, June 9, 2026. Peter...
- 5mo agoQNTGOOGLMSFTAMZN+8Quantinuum stock opens at $68 per share after IPOCNBCHoneywell will retain a majority stake in Quantinuum and will continue to be a strategic customer and partner following the listing.
- 5mo agoAMGNAMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026PR NewswireAmgen (NASDAQ:AMGN) today announced the presentation of new data across rare autoimmune and inflammatory diseases at the European Alliance of...
- 5mo agoAMGNEUROPEAN COMMISSION APPROVES AMGEN'S IMDYLLTRA® FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCERPR NewswireAmgen (NASDAQ:AMGN) today announced that the European Commission (EC) has granted marketing authorization for IMDYLLTRA® (tarlatamab) as a...
- 5mo agoAMGNAMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCEPR NewswireAmgen (NASDAQ:AMGN) will present at Jefferies Global Healthcare Conference at 9:55 a.m. ET on Thursday, June 4, 2026. Peter Griffith, executive vice...
- 5mo agoAMGNEmber LifeSciences announces new strategic investments boosting Series A to $27MPR NewswireEmber LifeSciences, Inc., ("Ember") a leading provider of revolutionary cold chain technology, today announced strategic investments from Amgen...
- 5mo agoAMGNAMGEN ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER PETER GRIFFITHPR NewswireAmgen (NASDAQ:AMGN) today announced the retirement of Peter Griffith, who has served as the company's executive vice president and chief financial...
- 6mo agoABBVAMGNJNJLNAI+1CNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense ResearchGlobeNewswireAUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Among the most guarded structures in human biology, the brain is also one of the hardest to treat. The blood-brain barrier (BBB), a
- 6mo agoAMGNApproval of Wezlana, Bla #761285FDA Approved DrugsApproval Date: 05/13/2026; Drug Name: Wezlana, Bla #761285; Active Ingredients: USTEKINUMAB-AUUB; Company: Amgen Inc; Submission Status: Approval; Application Number: 761285